

# Kevin Outterson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8384356/publications.pdf>

Version: 2024-02-01

73  
papers

6,128  
citations

236925

25  
h-index

133252

59  
g-index

74  
all docs

74  
docs citations

74  
times ranked

8369  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 318-327.	9.1	3,672
2	The global preclinical antibacterial pipeline. <i>Nature Reviews Microbiology</i> , 2020, 18, 275-285.	28.6	442
3	Antibiotic development – economic, regulatory and societal challenges. <i>Nature Reviews Microbiology</i> , 2020, 18, 267-274.	28.6	218
4	The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e51-e60.	9.1	161
5	International cooperation to improve access to and sustain effectiveness of antimicrobials. <i>Lancet</i> , The, 2016, 387, 296-307.	13.7	114
6	Repairing The Broken Market For Antibiotic Innovation. <i>Health Affairs</i> , 2015, 34, 277-285.	5.2	96
7	Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 500-505.	9.1	86
8	Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration’s Approved Antibiotics, 2010–2015. <i>Annals of Internal Medicine</i> , 2016, 165, 363.	3.9	81
9	An international legal framework to address antimicrobial resistance. <i>Bulletin of the World Health Organization</i> , 2015, 93, 66-66.	3.3	80
10	Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 488-504.	329.8	65
11	Antibiotic research and development: business as usual?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1604-7.	3.0	60
12	Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals. <i>Health Affairs</i> , 2010, 29, 1689-1696.	5.2	55
13	Will longer antimicrobial patents improve global public health?. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 559-566.	9.1	54
14	Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. <i>PLoS Medicine</i> , 2016, 13, e1002043.	8.4	54
15	Regulating Compounding Pharmacies after NECC. <i>New England Journal of Medicine</i> , 2012, 367, 1969-1972.	27.0	47
16	Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. <i>BMJ Global Health</i> , 2020, 5, e003091.	4.7	47
17	Designing development programs for non-traditional antibacterial agents. <i>Nature Communications</i> , 2019, 10, 3416.	12.8	46
18	Accelerating global innovation to address antibacterial resistance: introducing CARB-X. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 589-590.	46.4	45

#	ARTICLE	IF	CITATIONS
19	Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980â€“2009. Journal of Law, Medicine and Ethics, 2013, 41, 688-696.	0.9	38
20	What Will it Take to Address the Global Threat of Antibiotic Resistance?. Journal of Law, Medicine and Ethics, 2015, 43, 363-368.	0.9	36
21	Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS ONE, 2018, 13, e0205166.	2.5	33
22	Improving data sharing to increase the efficiency of antibiotic R&D. Nature Reviews Drug Discovery, 2021, 20, 1-2.	46.4	32
23	To the G20: incentivising antibacterial research and development. Lancet Infectious Diseases, The, 2017, 17, 799-801.	9.1	31
24	Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Translational Research, 2020, 220, 182-190.	5.0	27
25	Poverty tourism and the problem of consent. Journal of Global Ethics, 2011, 7, 337-348.	0.5	26
26	Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale Journal of Health Policy, Law, and Ethics, 2005, 5, 193-291.	1.5	26
27	Punishing Health Care Fraud â€” Is the GSK Settlement Sufficient?. New England Journal of Medicine, 2012, 367, 1082-1085.	27.0	25
28	Market-Based Licensing For HPV Vaccines In Developing Countries. Health Affairs, 2008, 27, 130-139.	5.2	23
29	Should Access to Medicines and TRIPS Flexibilities Be Limited to Specific Diseases?. American Journal of Law and Medicine, 2008, 34, 279-301.	0.2	23
30	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in Health, 2021, 24, 1828-1834.	0.3	22
31	The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law. University of Pittsburgh Law Review, 2005, 67, .	0.0	22
32	Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. Journal of Pharmaceutical Policy and Practice, 2018, 11, 8.	2.4	20
33	How Medicare Could Get Better Prices On Prescription Drugs. Health Affairs, 2009, 28, w832-w841.	5.2	19
34	What Will it Take to Address the Global Threat of Antibiotic Resistance?. Journal of Law, Medicine and Ethics, 2015, 43, 6-11.	0.9	19
35	Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Affairs, 2016, 35, 784-790.	5.2	19
36	Patent Buy-Outs for Global Disease Innovations for Low-and Middle-Income Countries. American Journal of Law and Medicine, 2006, 32, 159-173.	0.2	17

#	ARTICLE	IF	CITATIONS
37	A shot in the arm for new antibiotics. <i>Nature Biotechnology</i> , 2019, 37, 1110-1112.	17.5	17
38	Clinical Trial Transparency â€” Antidote to Weaker Off-Label-Promotion Rules?. <i>New England Journal of Medicine</i> , 2014, 371, 1-3.	27.0	16
39	Social, cultural and economic aspects of antimicrobial resistance. <i>Bulletin of the World Health Organization</i> , 2020, 98, 823-823A.	3.3	16
40	Improving antibiotic markets for long-term sustainability. <i>Yale Journal of Health Policy, Law, and Ethics</i> , 2011, 11, 101-67.	1.5	16
41	Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010â€”2020. <i>Clinical Infectious Diseases</i> , 2022, 74, 1183-1190.	5.8	15
42	The Ethics of Poverty Tourism. <i>Environmental Philosophy</i> , 2010, 7, 93-114.	0.1	14
43	A roadmap for sustainably governing the global antimicrobial commons. <i>Lancet, The</i> , 2019, 394, 1788-1789.	13.7	13
44	Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines. <i>Health Affairs</i> , 2021, 40, 1758-1765.	5.2	13
45	A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 59-65.	0.9	11
46	Antibacterial R&D at a Crossroads: Weâ€™ve Pushed as Hard as We Can â€” Now We Need to Start Pulling!. <i>Clinical Infectious Diseases</i> , 2021, 73, e4451-e4453.	5.8	11
47	Innovation in the preclinical antibiotic pipeline. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 744-745.	46.4	10
48	Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. <i>Clinical Infectious Diseases</i> , 2021, 72, e420-e421.	5.8	10
49	Agony in the Antipodes: The generic drug provisions of the Australia-USA Free Trade Agreement. <i>Journal of Generic Medicines</i> , 2005, 2, 316-326.	0.2	9
50	Higher First Amendment Hurdles for Public Health Regulation. <i>New England Journal of Medicine</i> , 2011, 365, e13.	27.0	9
51	Antibiotic resistance and antibiotic development â€” Author's reply. <i>Lancet Infectious Diseases, The</i> , 2008, 8, 212-214.	9.1	6
52	Foreword â€” Will HPV Vaccines Prevent Cervical Cancers Among Poor Women of Color?: Global Health Policy at the Intersection of Human Rights and Intellectual Property Law. <i>American Journal of Law and Medicine</i> , 2009, 35, 247-252.	0.2	6
53	Questions about the 10 Å— 20 Initiative. <i>Clinical Infectious Diseases</i> , 2010, 51, 751-752.	5.8	6
54	Smoking and the First Amendment. <i>New England Journal of Medicine</i> , 2011, 365, 2351-2353.	27.0	6

#	ARTICLE	IF	CITATIONS
55	Poverty Tourism, Justice, and Policy. <i>Public Integrity</i> , 2011, 14, 39-50.	1.0	6
56	The effect of generic market entry on antibiotic prescriptions in the United States. <i>Nature Communications</i> , 2021, 12, 2937.	12.8	6
57	Combating Antibiotic Resistance Through the Health Impact Fund. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
58	Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 63-65.	1.3	5
59	Disease-based Limitations on Compulsory Licenses Under Articles 31 and 31bis. , 2010, , .		4
60	Pharmaceutical Innovation: Law & the Public's Health. <i>Journal of Law, Medicine and Ethics</i> , 2009, 37, 173-175.	0.9	3
61	The Ethics of Poverty Tourism. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
62	Testimony of Kevin Outterson (Boston University School of Law) to the House Energy and Commerce Committee, September 19, 2014. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
63	Germ Shed Management in the United States. , 2012, , 163-181.		2
64	GP corporatisation: lessons to be learned. <i>Medical Journal of Australia</i> , 2001, 175, 426-427.	1.7	1
65	Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. <i>SSRN Electronic Journal</i> , 2016, , .	0.4	1
66	The impact of infections on reimbursement in 92 US hospitals, 2015-2018. <i>American Journal of Infection Control</i> , 2021, 49, 1275-1280.	2.3	1
67	Access to Global Disease Innovation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
68	The Fight Against Multidrug-Resistant Bacteria. <i>Annals of Internal Medicine</i> , 2017, 166, 79.	3.9	0
69	Resolving Dysfunctional Pharmaceutical Arbitrage and Counterfeiting through the Proposed Hubbard-Love R&D Treaty. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
70	Nonrival Access to Pharmaceutical Knowledge. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
71	US Senate Health, Education, Labor, & Pensions Committee Hearing on Drug Importation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
72	William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc., et al. - Amicus Brief in Support of Petitioners. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
73	Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach. SSRN Electronic Journal, 0, , .	0.4	0